STOCK TITAN

Altimmune Inc - ALT STOCK NEWS

Welcome to our dedicated news page for Altimmune (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Altimmune's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Altimmune's position in the market.

Rhea-AI Summary
Altimmune, Inc. (Nasdaq: ALT) announced an abstract on pemvidutide in subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease will be presented at the NASH-TAG Conference. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH. The presentation will discuss the correlation between Pemvidutide-induced liver fat reduction and improvements in non-invasive markers of inflammation and fibrosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.49%
Tags
clinical trial
-
Rhea-AI Summary
Altimmune, Inc. (Nasdaq: ALT) announces topline results from the 48-week MOMENTUM Phase 2 obesity trial of pemvidutide. The trial enrolled 391 subjects, achieving a mean weight loss of 15.6% on the 2.4 mg dose at Week 48. Over 30% of subjects achieved 20% or more weight loss on the same dose. Robust reductions in BMI and serum lipids and improvements in blood pressure were observed without imbalances in cardiac events, arrhythmias, or clinically meaningful increases in heart rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.97%
Tags
clinical trial
-
Rhea-AI Summary
Altimmune, Inc. (Nasdaq: ALT) announced financial results and key milestones, including the 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023, Fast Track designation for pemvidutide in NASH treatment, and top-line results from the Phase 2 HepTcell™ trial in chronic hepatitis B expected Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
earnings
Rhea-AI Summary
Altimmune, Inc. will report its third quarter 2023 financial results on November 7, 2023. The company will also provide a business update. A conference call will be hosted by Altimmune management at 8:30 am E.T. on November 7 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website. A replay will be available on the Investor Relations website for up to three months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
conferences earnings
-
Rhea-AI Summary
Altimmune receives Fast Track designation from FDA for pemvidutide in the treatment of NASH
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags
clinical trial
-
Rhea-AI Summary
Altimmune to present new data on pemvidutide's anti-inflammatory and anti-fibrotic properties in NAFLD at The Liver Meeting® 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
conferences
Rhea-AI Summary
Altimmune, Inc. to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
conferences
-
Rhea-AI Summary
Altimmune announces results of 24-week clinical trial of pemvidutide for obesity treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
clinical trial
-
Rhea-AI Summary
Altimmune completes dosing in Phase 2 MOMENTUM trial for pemvidutide in obesity and overweight subjects
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.41%
Tags
clinical trial
Rhea-AI Summary
Altimmune to participate in investor conferences, including Wells Fargo 2023 Healthcare Conference and Morgan Stanley 21st Annual Global Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
conferences
Altimmune Inc

Nasdaq:ALT

ALT Rankings

ALT Stock Data

608.21M
50.42M
0.88%
62.56%
18.63%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Gaithersburg

About ALT

altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current